The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection serves only as a preliminary check |
| Solubility | Freely soluble in water and aqueous buffers | Gentle mixing may be needed to reach full dissolution |
| Typical storage | Minus 20 degrees Celsius or colder, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Primary analytical method | Reversed-phase HPLC with mass detection | Purity reported as chromatographic area percent |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes are distinct from approved product names |
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Study 402 patients saw an improvement of depressive symptoms compared to placebo as documented by a change in MADRS total score of 2.4. Study 401 was conducted solely in the United States while Study 404 was a global study and included patients from the US. Of the entire Study 404 population (381 patients), two-thirds were from Russia and Colombia. At the completion of the two monotherapy Phase III trials only Study 404 met its primary endpoint and one of its secondary endpoints. In Study 404, patients received 42 mg lumateperone once daily or placebo for six weeks. Study 404 patients saw an improvement of depressive symptoms compared to placebo as documented by a change in MADRS total score of 4.6.
=== COVID-19 === In 2021, dimethyl fumarate was evaluated as a treatment for COVID-19 as part of the RECOVERY Trial in the UK. The results of the trial found that dimethyl fumarate did not significantly improve clinical outcomes in hospitalized COVID-19 patients.
Taco Bell opened its first Malaysian store in Cyberjaya, Sepang on April 2, 2021. It then opened its second store in Bandar Sri Permaisuri, Kuala Lumpur followed by Tropicana Gardens Mall and Setiawangsa outlets. In early 2022, Taco Bell opened up in Wangsa Maju, Sunway Pyramid, Puchong and has continued in expanding to other states as well. It currently has 13 stores scattered across Klang Valley.
Sources: en.wikipedia.org
On 10 December 2009, Mgr Yves Le Saux, Bishop of Le Mans, France, opened the diocesan process for the beatification of Zita. Zita was in the habit of spending several months each year in the diocese of Le Mans at St. Cecilia's Abbey, Solesmes, where three of her sisters were nuns. The actor is the French Association pour la Béatification de l'Impératrice Zita. The postulator for the cause is Alexander Leonhardt. Vice postulator for Hungary is Catholic theologian Norbert Nagy. The judge of the tribunal is Bruno Bonnet. The promoter of justice is François Scrive. With the opening of her cause, the late Empress has been named Servant of God.
These enzymes cleave the β-lactam ring, an essential component of β-lactam antibiotics that are recognized by and bound to PBPs. Carbapenemases are divided into different classes, depending on the structure of the enzyme and the mechanism by which they hydrolyze the β-lactam ring. The two broad categories of carbapenemases are serine-carbapenemases, which contain serine at the active site, and metallocarbapenemases, which contain zinc at the active site. Class A carbapenemases are serine carbapenemases and are encoded on either the chromosome of the bacteria or a plasmid. A serine at position 70 at the active site of this class of enzymes is required for hydrolysis of β-lactams to occur. Class D carbapenemases, also referred to as the OXA β-lactamases, are serine β-lactamases. They are encoded on plasmids and contain a large variability in amino acid sequence. The resistance mechanism for class D carbapenemases is caused by the formation of an acyl intermediate when breaking the β-lactam ring. Class B carbapenemases are metallolactamases and require a zinc at the active site for hydrolysis. A clinical isolate of E. coli from the sputum sample of a patient admitted to a Beijing hospital was found to acquire resistance to carbapenem through mutations not previously observed. It involved a mutation of a regulator gene marR and the expression of a normally nontranslated membrane porin yedS; both mutations were demonstrated to have effects on the ability of this strain of E.coli to resist carbapenems.
In contrast, CD8 T cells (in general, killer T cells) are able to recognize MHC class I molecules through the α3 domain of MHC class I (it does not recognize β2 microglobulin). T cell receptors are, in general, highly specific to particular peptide-MHC complexes. Some peptide sequences can only be presented by a specific type of MHC protein because they require specific amino acid sequences within the binding groove to associate with them. These are known as MHC-restricted peptides. If an individual does not express the relevant MHC protein needed for a given MHC-restricted peptide, they will not be able to present that antigen to T cells. This can be an important consideration in the design of vaccines, as a robust immune response should be generated in every vaccinee, which will not be possible if it has too many MHC-restricted peptide sequences and the vaccinee does not express the correct MHC polymorphism for effective presentation to T cells. Because the T cell receptor cannot recognize anything not presented on an MHC, conventional (see next paragraph) T cells are not capable of responding to non-peptide antigens (lipids, carbohydrates, etc), except in the case of post-translational modifications to peptides that end up being presented.
Sources: en.wikipedia.org
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.
Lower temperatures slow most degradation routes, and storage at minus twenty degrees Celsius or below is standard for lyophilized material. Repeated warming and cooling imposes stress on the molecule. Dissolved samples deteriorate faster and are usually handled over shorter periods.
It normally reflects the relative chromatographic area of the principal peak. It does not capture every possible impurity or demonstrate biological function. Additional methods are required to describe a sample completely.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.